Transplantation & Cellular Therapy
Transplantation & Cellular Therapy
The latest news, research, and perspectives in transplantation and cellular therapy. Hematopoietic cell transplantation involves replacing unhealthy bone marrow with healthy stem cells in patients with hematologic disorders. In the growing field of non-transplant cellular therapies, including chimeric antigen receptor T-cell therapies, patient- or donor-derived cells are being explored for the treatment and potential cure of blood cancers.
Magdi Elsallab, MD, PhDTransplantation & Cellular Therapy | April 17, 2024
In approximately 12,000 reports of adverse events, the researchers found 19 cases of T-cell malignancies after CAR-T.
View More
Melissa BadamoTransplantation & Cellular Therapy | April 5, 2024
The investigators reviewed case reports of patients 20 years old and younger who underwent therapy for BPDCN.
Sarah ValentineAcute Myeloid Leukemia | April 2, 2024
HMA plus venetoclax was found to be effective and well tolerated in patients with AML who relapsed after HSCT.
Sarah ValentineAggressive B-Cell Lymphoma | March 26, 2024
Adding ofatumumab to reduced intensity conditioning is safe and effective in high-risk B-cell non-Hodgkin lymphoma.
Douglas Tremblay, MDMyelodysplastic Syndromes | March 15, 2024
The study also explored the role of this combination in transitioning patients to HSCT.
Melissa BadamoAcute Myeloid Leukemia | March 7, 2024
The award grants $100,000 to a postdoctoral or early-career oncology researcher from a racial/ethnic minority group.
Cecilia BrownIndolent B-Cell Lymphoma | March 8, 2024
The multicenter, single-arm phase II trial evaluated axicabtagene ciloleucel in patients with MZL or follicular lymphoma.
Nicolaus Kröger, MDMyelofibrosis | March 4, 2024
Nicolaus Kröger, MD, discusses a study on GVHD and its impact on relapse in patients with myelofibrosis undergoing HSCT.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | February 29, 2024
Drs. Dahiya and Spiegel return for the second half of a discussion on reports of secondary T-cell malignancies after CAR-T.
Richard Newcomb, MDTransplantation & Cellular Therapy | February 26, 2024
Approach-oriented coping was associated with higher quality of life and lower symptoms of depression and anxiety.
Melissa BadamoMyeloma | March 19, 2024
The study used public data from various online sources related to approved CAR-T therapies for MM.
Shambavi Richard, MDTransplantation & Cellular Therapy | February 20, 2024
The mandate could affect moving CAR-T therapies into earlier lines of therapy for multiple myeloma.
Melissa BadamoPrint | February 8, 2024
This manufacturing process change results in a shorter manufacturing time for axi-cel from 16 days to 14 days.
Patrick DalyPrint | February 7, 2024
ZUMA-7 showed that axi-cel significantly improved OS compared with standard of care in relapsed or refractory LBCL.
Chadi Nabhan, MD, MBA, FACPTransplantation & Cellular Therapy | January 26, 2024
The latest HemOnc Pulse episode looks at the science behind the statement from the FDA on the risk of CAR-T therapies.
Patrick DalyTransplantation & Cellular Therapy | February 2, 2024
Patients' coping strategies prior to HSCT had significant effects on their psychological distress and quality of life.
Blood Cancer TalksBlood Cancer Talks | January 24, 2024
Shernan Holtan, MD, and the hosts discuss recent data on graft versus host disease prophylaxis.
Leah SherwoodTransplantation & Cellular Therapy | January 5, 2024
GVHD affects approximately 30,000 Americans, according to Dr. Michael Chancellor, Chief Medical Officer at Lipella.
Ajai Chari, MDTransplantation & Cellular Therapy | January 24, 2024
The investigation is "likely not going to change the risk-benefit profile of these approved products," Dr. Chari said.
Afaf Osman, MDAcute Myeloid Leukemia | March 5, 2024
Dr. Osman discussed menin inhibitors for leukemia, and axatilimab treatment for graft-versus-host disease.
Editorial Board